6,7,4'-Trihydroxyisoflavone
CAS No. 17817-31-1
6,7,4'-Trihydroxyisoflavone( —— )
Catalog No. M22805 CAS No. 17817-31-1
6,7,4'-Trihydroxyisoflavone, is a novel inhibitor of PKCα in suppressing solar UV-induced matrix metalloproteinase 1, which has antioxidant, and anti-cancer activities.Molecular studies showed that 6,7,4'-THIF significantly inhibited acetylcholinesterase and thiobarbituric acid reactive substance (TBARS) activities in the hippocampus of scopolamine-induced mice.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 10MG | 38 | In Stock |
|
| 25MG | 69 | In Stock |
|
| 50MG | 99 | In Stock |
|
| 100MG | 145 | In Stock |
|
| 200MG | 212 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name6,7,4'-Trihydroxyisoflavone
-
NoteResearch use only, not for human use.
-
Brief Description6,7,4'-Trihydroxyisoflavone, is a novel inhibitor of PKCα in suppressing solar UV-induced matrix metalloproteinase 1, which has antioxidant, and anti-cancer activities.Molecular studies showed that 6,7,4'-THIF significantly inhibited acetylcholinesterase and thiobarbituric acid reactive substance (TBARS) activities in the hippocampus of scopolamine-induced mice.
-
Description6,7,4'-Trihydroxyisoflavone, is a novel inhibitor of PKCα in suppressing solar UV-induced matrix metalloproteinase 1, which has antioxidant, and anti-cancer activities.Molecular studies showed that 6,7,4'-THIF significantly inhibited acetylcholinesterase and thiobarbituric acid reactive substance (TBARS) activities in the hippocampus of scopolamine-induced mice.In addition, immunohistochemistry and Western blot results revealed that 6,7,4'-THIF significantly increased brain-derived neurotrophic factor (BDNF) and phosphor cAMP response element binding (CREB) in the hippocampus of mice. A single administration of 6,7,4'-THIF significantly improved scopolamine-induced cognitive dysfunction in these in vivo tests. Moreover, treatment with 6,7,4'-THIF alone enhanced learning and memory performance in the same behavioral tests. 6,7,4'-THIF improves cognitive dysfunction induced by scopolamine and enhances learning and memory by activation of the cholinergic system and the p-CREB/BDNF signaling pathway in mice.
-
In VitroDesmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppessesanchorage-dependent growth of HCT-116 and DLD1 cells in a dose- and time-dependent manner without cytotoxicity.Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppresses CDK1 activity in a dose-dependent manner andinhibits CDK2 activity in HCT-116 cells.Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) induces cell cycle arrest at the S and G2/M phases, the percentage of cells in S phase is higher in the 100 μM 6,7,4′-THIF-treated group, and the same pattern is observed in G2/M phase (29.5% versus 19.1% ) . Cell Viability Assay Cell Line:HCT-116 cells Concentration:0, 12.5, 25, 50 or 100 μM Incubation Time:24, 48 or 72 hours Result:Inhibited anchorage-dependent and -independent growth of HCT-116 cells.Western Blot Analysis Cell Line:HCT-116 and DLD1 cells Concentration:0, 25, 50 or 100 μM Incubation Time:48 hours Result:Inhibited CDK1,CDK2 expression.Cell Cycle Analysis Cell Line:HCT-116 cells Concentration:0, 25, 50 or 100 μM Incubation Time:24, 48 or 72 hours Result:Induces cell cycle arrest of HCT-116 cells at S and G2/M phases.
-
In VivoDesmethylglycitein (4',6,7-Trihydroxyisoflavone) (intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days) suppresses tumor development in mice and serves as an effective anticancer treatment with the potential to inhibit or delay the tumorigenicity of HCT-116 cells in an in vivo system. Animal Model:Female athymic nude mice subcutaneously injected with HCT-116 cells Dosage:5 or 25 mg/kg Administration:Intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days Result:Decreased tumor growth, volume and weight of HCT-116 xenografts.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPKC
-
RecptorCDK1|CDK2|PKC
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number17817-31-1
-
Formula Weight270.2
-
Molecular FormulaC15H10O5
-
Purity>98% (HPLC)
-
SolubilityDMSO:125 mg/mL (462.55 mM; Need ultrasonic)
-
SMILESO=C1C(C2=CC=C(O)C=C2)=COC3=CC(O)=C(O)C=C13
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
D-ERYTHRO-SPHINGOSIN...
D-erythro-Sphingosine is a protein kinase C (PKC) inhibitor. D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator.
-
HG-9-91-01
HG-9-91-01 is a potent and highly selective salt-inducible kinase (SIKs) inhibitor with?IC50s of 0.92 nM, 6.6 nM and 9.6 nM for?SIK1, ?SIK2?and?SIK3respectively.
-
PKC β pseudosubstrat...
Selective cell-permeable peptide inhibitor of protein kinase C (IC50 ~ 0.5 μM). Consists of amino acids 19 - 31 of PKC pseudosubstrate domain linked by a disulphide bridge to a cell permeabilisation Antennapedia domain vector peptide. The Antennapedia peptide is actively taken up by intact cells, at 4 or 37°C, ensuring rapid and effective uptake of the inhibitor peptide. Once inside the cell, the disulphide bonds are subjected to reduction in the cytoplasm leading to release of the inhibitor peptide.
Cart
sales@molnova.com